3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Red Robin directors James C. Pappas and Christopher Martin resigned from the board and all committees, effective October 23, 2026, and the company said the resignations were not related to any disagreement over operations, policies or practices. The company plans to cut the board from eight to six directors, five of whom will be independent, and says the departures follow its refranchising program and a new $115 million credit facility.
Pappas (JCP Investment Management) and Martin (Jumana Capital) resigned effective October 23, 2026.
Board size will decrease from eight to six directors, five of whom will be independent.
New five-year, $115 million senior secured credit facility, led by JPMorgan Chase Bank, N.A., includes a $90 million term loan and a $25 million revolving credit facility.
Pappas and Martin joined the board in December 2024 in connection with an additional investment by Jumana and JCP.
Spero Therapeutics announced that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years with the company. He is expected to serve as a consultant through approximately February 28, 2027 to support the leadership transition.
Timothy Keutzer, Chief Operating Officer, retires effective December 31, 2026
Consulting arrangement expected to run until approximately February 28, 2027, terminable by either party on fifteen days' written notice
Keutzer will be paid an hourly rate during the consulting period; the filing gives no dollar figure
Enerpac Tool Group amended the offer letter of President and CEO Paul Sternlieb, setting out how his equity and cash incentives would be treated if he retires after a specified date, with a retirement date no earlier than July 31, 2030. The amendment also raises his change-in-control and severance benefits, which the company says is meant to keep him in the role and support a leadership transition.
Amendment dated October 26, 2026 sets a retirement notice period of 180 days, with windows starting in February 2030.
Severance multiples rise to 2 times base salary and annual incentive from 1.5 times; welfare premium coverage rises to 24 months from 18 months.
Legal fee reimbursement limits rise to $50,000 from $10,000 for enforcing severance terms, plus up to $50,000 for negotiating the amendment.
The amendment does not change Mr. Sternlieb's base salary, target bonus, or annual long-term equity award opportunity.
Sunbelt Rentals' General Counsel and Corporate Secretary, Lynne Fuller-Andrews, stepped down from her executive role on October 23, 2026, and will remain with the company in a non-executive capacity until her retirement on November 1, 2027. The company has started a search for her replacement. The filing describes a retirement agreement with a base salary and bonus, but the change is a planned leadership transition rather than a change in financial results.
Lynne Fuller-Andrews stepped down as Executive Vice President, General Counsel and Corporate Secretary effective October 23, 2026.
She will stay in a non-executive role through her retirement date of November 1, 2027.
Retirement agreement provides a base salary of $637,500 during the transition period and a cash bonus of $510,000 for fiscal year ending April 30, 2027.
The company has commenced a search for its next General Counsel.
Fortune Brands Innovations, Inc. announced several leadership changes, including Executive Vice President and Chief Operating Officer Dave Barry's move to lead the Moen business and the hiring of Peter DuBois as Chief Information Officer. The company said the changes are meant to give its businesses more focus and speed up execution, and the filing gives no financial figures for the changes.
Dave Barry moves from Executive Vice President and Chief Operating Officer to Executive Vice President and President, Moen; the company determined this on October 22, 2026
Peter DuBois joins as Executive Vice President and Chief Information Officer effective November 2, 2026, reporting to CEO Jesse Singh; he previously was Chief Digital and Technology Officer of Serta Simmons Bedding
John D. Lee moves to Executive Vice President and Chief Innovation Officer effective November 2, 2026, and will focus on R&D and Consumer Services
Rachel Roberts becomes Chief Commercial Officer for Moen; Matt Zimmer, General Manager of House of Rohl since June 2026, will report directly to Singh
Cardiff Oncology said its Chief Medical Officer, Roger Sidhu, separated from the company on October 22, 2026, in a mutually agreed transition. The company appointed Dr. Leila Alland as interim Chief Medical Officer under a consulting agreement, and it also increased its authorized common stock to 300,000,000 shares. The filing does not include financial results or guidance.
Roger Sidhu separated from the company as Chief Medical Officer on October 22, 2026, in a mutually agreed transition.
Dr. Leila Alland's consulting agreement began October 23, 2026, and runs until April 22, 2027, or earlier if all services are completed.
Dr. Alland will be paid a monthly fee of $35,000 and will devote up to 50% of her professional time to the role.
Authorized common stock was increased to 300,000,000 shares, effective October 22, 2026.
AIAI Holdings Corp disclosed that director Eric Affeldt resigned from its Board of Directors, effective October 21, 2026, the day he notified the board. The filing states the resignation was not due to any dispute or disagreement with the company or its board on operations, policies or practices.
Eric Affeldt notified the board of his intention to resign on October 21, 2026, effective the same day
The filing states there was no dispute or disagreement behind the resignation
Filing dated October 27, 2026, signed by CEO Todd Furniss
Edward Mathers resigned from the Senti Biosciences board and all its committees, effective immediately, on October 27, 2026. The Board also set October 30, 2026 as the record date for the previously announced distribution of contingent value rights (CVRs) tied to the merger that closed October 21, 2026.
Edward Mathers resigned from the Board and all committees, effective immediately on October 27, 2026.
Board fixed close of business on October 30, 2026 as the record date for the CVR distribution.
CVRs relate to the merger agreement dated July 14, 2026, which closed October 21, 2026.
CooperCompanies said Albert G. White III stepped down as President, Chief Executive Officer and director on October 27, 2026, and independent director Walter M. Rosebrough, Jr. was named interim Executive Chair. The press release said the company's recent performance has not met expectations, and the company reaffirmed its fiscal 2026 guidance. Shareholders face a leadership change while a permanent CEO is sought, and the board is changing composition with Shlomo Nachman joining in December 2026 and three directors not seeking reelection.
Albert G. White III resigned as President, CEO and director effective October 27, 2026, and will remain a strategic advisor through April 1, 2027.
Walter M. Rosebrough, Jr. was appointed interim Executive Chair effective immediately; a CEO Search Committee of Lawrence E. Kurzius, Cynthia L. Lucchese and Teresa S. Madden will oversee the CEO search.
Shlomo Nachman will join the board effective December 8, 2026; Barbara Carbone, Colleen E. Jay and Robert S. Weiss will not stand for reelection at the 2027 Annual Meeting.
The company reaffirmed its fiscal 2026 guidance provided on September 9, 2026.
Goodyear said Jerome J. Rouquet, currently CFO of Visteon Corporation, will become Executive Vice President and Chief Financial Officer effective December 1, 2026. Scott M. Deakin continues as Interim CFO through November 30, 2026. The filing also details a compensation package for Rouquet, which includes a base salary of $900,000 and a long-term incentive award valued at $3,200,000.
Jerome J. Rouquet becomes EVP and CFO effective December 1, 2026; Scott M. Deakin serves as interim CFO through November 30, 2026
Rouquet has been SVP and CFO of Visteon Corporation since February 2020; he is 59 years old
Base salary of $900,000 and target annual incentive of $900,000
Make-whole and inducement awards include a $2,500,000 cash payment on March 15, 2027 and Restricted Stock Unit awards of $2,600,000 and $700,000
Allegiant Travel Company disclosed that director Jude Bricker resigned from its Board of Directors after taking on new responsibilities as an owner and chief executive of a newly formed company that has agreed to buy a U.S. charter airline. The Board accepted the resignation as of October 23, 2026, under a company policy requiring directors to offer to resign after significant personal or job changes. The filing does not describe any effect on company operations or finances.
Jude Bricker submitted his resignation letter to the Board on October 16, 2026.
The Board accepted the resignation effective October 23, 2026.
Resignation follows Bricker's role as owner and CEO of a newly formed company that has agreed to purchase a U.S. charter airline.
The filing was signed by Robert Neal, President and Chief Financial Officer, on October 27, 2026.
Visteon said Chief Financial Officer Jerome Rouquet will leave the company effective November 30, 2026, to pursue other opportunities. Colleen Myers, the company's Vice President and Chief Accounting Officer, will serve as interim CFO and principal financial officer while the board searches for a permanent successor. The filing states the departure is not the result of any disagreement over operations, policies, controls or accounting.
Jerome Rouquet, Senior Vice President and CFO, leaves effective November 30, 2026
Colleen Myers, 51, named interim CFO; she has been Chief Accounting Officer since January 2024 and joined Visteon in June 2015
Myers receives a $25,000 monthly stipend while interim CFO; annual base salary rises from $286,000 to $330,000
Charter Communications disclosed that its board declared a quarterly cash dividend on its Series A Cumulative Redeemable Preferred Stock, and that its compensation committee approved pay for Kevin Howard while he serves as interim Chief Financial Officer. The dividend is a routine declaration for preferred holders, while the compensation terms show the terms set for the interim CFO role.
Preferred dividend of $0.43750001 per share, payable January 15, 2027, to holders of record at the close of business on December 31, 2026
Kevin Howard, interim CFO, to receive an annual base salary of $925,000 and a target annual cash bonus of 175% of base salary
Howard granted restricted stock units with a grant date fair value of $250,000 on October 26, 2026, cliff vesting on the third anniversary of the grant date
Hasbro announced that Dan Ayoub, most recently Senior Vice President of Dungeons & Dragons, will become President of Wizards of the Coast and Hasbro Digital Games effective November 2, 2026. He is the first internal candidate promoted into the role, and he will oversee Magic: The Gathering, Dungeons & Dragons, Duel Masters and Hasbro Digital Games. The filing contains no financial results or guidance.
Dan Ayoub named President of Wizards of the Coast & Hasbro Digital Games, effective November 2, 2026
He is the first internal candidate promoted into the role, selected after a search of dozens of internal and external candidates
Ayoub joined Wizards of the Coast in 2022 and previously spent 11 years at Microsoft
CEO Chris Cocks said the promotion reflects a priority of developing the company's people
American Public Education (APEI) appointed Shira Goodman, former Staples CEO, as a director effective October 27, 2026, and named her to the Audit Committee and the Management Development and Compensation Committee. The filing also says James Kenigsberg, who left the board last year, was made permanent chief innovation and technology officer, which is a routine board addition with no financial results disclosed.
Goodman's term runs to the 2027 Annual Meeting of Stockholders; she was appointed by the board on October 22, 2026.
Non-employee director pay includes an annual cash retainer of $80,000 and restricted stock valued at $110,000, pro-rated for 2026.
Goodman fills the board seat left by James Kenigsberg, who now serves permanently as chief innovation and technology officer.
Columbia Banking System said Torran Nixon, Co-President of Columbia Bank and Senior Executive Vice President, will transition to a senior advisor role. The change takes effect July 1, 2027 or another agreed date, and he is set to retire December 31, 2027. The filing describes continued pay and equity terms, which matter to shareholders as a planned leadership change at a senior level.
Transition Date: July 1, 2027, or another mutually agreed date
Retirement Date: December 31, 2027, after service as senior advisor
Nixon eligible for a 2027 equity grant with target grant date fair value no less than his 2026 grant while Co-President
Annual incentive payout for 2027, if any, prorated through the Transition Date
Merlin's Board appointed Mark Brunner, the company's Chief Revenue Officer since April 2026, as President effective immediately, according to the filing dated October 27, 2026. Matthew George remains Chief Executive Officer and Chairman, so the change adds a President role without changing the top executive or board leadership.
Mark Brunner, age 60, was appointed President effective immediately on October 27, 2026, and continues to be listed as Chief Revenue Officer, a role he has held since April 2026.
Matthew George remains Chief Executive Officer and Chairman of the Board.
Brunner previously served as Executive Vice President, Public Sector at PsiQuantum (July 2024 to March 2026) and as President, Public Sector at Primer AI (January 2022 to July 2024).
The filing states no arrangements or understandings tied to the appointment and no related-party transactions requiring disclosure.
BlackBerry appointed David Chaikof to its Board of Directors, effective October 27, 2026, and the board increased from eight to nine directors. The filing says the Board determined he is independent, and that his compensation matches other non-employee directors. The filing reports no financial results or guidance, so the change is a governance update rather than a financial one for shareholders.
Board appointment effective October 27, 2026; board size increases from eight to nine directors
Eight of nine directors, including Mr. Chaikof, are independent per the Board's determination
Mr. Chaikof previously served as external counsel to BlackBerry for more than a decade while at Torys LLP
Compensation and indemnification match the company's other non-employee directors
Lifeward Ltd. said its Board appointed Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. The filing describes his prior CFO roles at IceCure Medical, Insuline Medical and Mer-Group, and his pay terms are tied to shareholder approval of a renewed compensation policy at the October 30, 2026 annual meeting.
Appointed by the Board on October 26, 2026; effective November 1, 2026
Gross monthly base salary of NIS 70,000, plus an annual performance-based bonus with a target of not less than four monthly salaries
Three-month termination notice, rising to four months for either party after a change in the CEO
Altimmune said its board appointed Peter Greenleaf and Alex Howarth as directors effective November 2, 2026, increasing the board from nine to eleven seats. Three current directors, John Gill, Mitchel Sayare and Klaus Schafer, will retire at the 2027 annual meeting rather than stand for re-election, and the company said their departures are not due to any disagreement with the company.
Peter Greenleaf (54), former CEO of Aurinia Pharmaceuticals, and Alex Howarth (58), former CFO of Madrigal Pharmaceuticals, join the board effective November 2, 2026.
Board size increases from nine to eleven directors.
Gill, Sayare and Schafer continue as directors until the 2027 Annual Meeting, then retire.
Each new director receives an initial stock option award for 160,000 shares and a $40,000 annual cash retainer.
Axcelis Technologies appointed Jeroen Delsman, formerly a Vice President at Ferrotec USA, as Executive Vice President and Chief Financial Officer effective November 12, 2026, succeeding interim CFO David Ryzhik, who will move to Senior Vice President of Corporate Development and Investor Relations. The filing details a $500,000 base salary and sign-on awards, and notes the appointment is tied to the pending merger with Veeco.
Jeroen Delsman appointed EVP and CFO by the Board on October 24, 2026, effective November 12, 2026
Base salary of $500,000, with a 75% target under the Axcelis Team Incentive plan starting in 2027
Sign-on RSU award with grant date value of $1,200,000, plus a $352,000 sign-on cash bonus and an $80,000 relocation bonus
David Ryzhik moves from interim CFO to Senior Vice President, Corporate Development and Investor Relations, reporting to CEO Russell Low
Entera Bio's board appointed Dr. Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon, as a Class II director effective December 1, 2026, and he will join the compensation committee. Director Haya Taitel is stepping down from the board on the same date, and the filing says her departure was not due to any disagreement with the company.
Dr. Arjona Ferreira is the Head of R&D and Chief Medical Officer at Organon & Co. (NYSE: OGN) and previously held roles at Myovant Sciences, Shionogi and Merck & Co.
Board appointment is effective December 1, 2026, and he will serve until the 2027 Annual Meeting of Shareholders.
Haya Taitel notified the board on October 27, 2026 that she will step down as a director effective December 1, 2026.
The board determined Dr. Arjona Ferreira is independent under SEC and Nasdaq rules.
Faeth Therapeutics' board increased its size from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director effective immediately. Dr. Schayowitz currently serves as Executive Vice President and Head of Research and Development at Zymeworks Inc., and his board seat comes with a cash retainer and an option to buy 25,000 shares.
Board expanded from six to seven directors; appointment made October 23, 2026, effective immediately
Dr. Schayowitz (age 46) is EVP and Head of Research and Development at Zymeworks Inc. since April 2026
Initial equity award is an option on 25,000 shares under the 2026 Equity Incentive Plan, vesting monthly through the third anniversary of grant
First Horizon Corporation's boards elected Jeffrey R. Balser, a physician and academic health system executive, to the board effective October 26, 2026, and amended the bylaws to increase the board from twelve to thirteen members. The filing reports no financial results, and the changes are governance matters that add one board seat and one new director.
Jeffrey R. Balser elected to the board effective immediately on October 26, 2026.
Balser is President and CEO of Vanderbilt University Medical Center and Dean of Vanderbilt University School of Medicine.
Balser appointed to the Nominating and Corporate Governance Committee and the Information Technology Committee.
Bylaw Section 3.2 amended October 26, 2026 to set the board at thirteen members, up from twelve.
Hycroft Mining reported third-quarter 2026 results and said it held $211 million in unrestricted cash with no debt, but the filing does not include revenue, earnings or production figures. The company also said CFO Stanton Rideout will move to an advisory role effective March 16, 2027, and that a senior vice president will retire, so shareholders will see a change in finance leadership.
Q3 2026 results: $211 million in unrestricted cash and no debt; the filing gives no revenue, profit or EPS figures
CFO Stanton Rideout moves to Executive Vice President, Strategic Advisor effective March 16, 2027; search for a replacement has started
SVP David Thomas to retire; the 8-K gives March 31, 2027, while the press release gives April 30, 2027
Michael Deal named Chief Operating Officer; four new independent directors appointed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.